On Nov 19, major Wall Street analysts update their ratings for $Twist Bioscience (TWST.US)$, with price targets ranging from $35 to $58.
J.P. Morgan analyst Rachel Vatnsdal maintains with a sell rating, and maintains the target price at $35.
Barclays analyst Luke Sergott maintains with a buy rating, and maintains the target price at $52.
TD Cowen analyst Brendan Smith maintains with a buy rating, and maintains the target price at $58.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and adjusts the target price from $46 to $48.
Furthermore, according to the comprehensive report, the opinions of $Twist Bioscience (TWST.US)$'s main analysts recently are as follows:
Twist Bioscience had a strong recent quarter and appears set to meet its projections of 50% gross margins by Q4. This performance comes amidst a challenging budgetary environment, yet the company's outlook for fiscal 2025 remains promising.
Twist Bioscience showed broad-based solid performance, with each segment modestly surpassing revenue expectations as compared to guidance. The sustained momentum in synthetic biology and next-generation sequencing, along with discussions related to the Express portfolio, and general margin percentage improvements, foster a constructive outlook heading into FY25.
Here are the latest investment ratings and price targets for $Twist Bioscience (TWST.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月19日，多家華爾街大行更新了$Twist Bioscience (TWST.US)$的評級，目標價介於35美元至58美元。
摩根大通分析師Rachel Vatnsdal維持賣出評級，維持目標價35美元。
巴克萊銀行分析師Luke Sergott維持買入評級，維持目標價52美元。
TD Cowen分析師Brendan Smith維持買入評級，維持目標價58美元。
貝雅分析師Catherine Ramsey Schulte維持買入評級，並將目標價從46美元上調至48美元。
此外，綜合報道，$Twist Bioscience (TWST.US)$近期主要分析師觀點如下：
twist bioscience最近一個季度表現強勁，並計劃在第四季度實現50%的毛利率目標。 這一表現是在一個具挑戰性的預算環境中取得的，然而公司對2025財年的前景仍然看好。
twist bioscience表現穩健，各業務板塊的收入都略高於預期，與指導情況相比。合成生物學和下一代測序領域的持續勢頭，以及與Express投資組合相關的討論，以及一般邊際百分比的改善，爲FY25的前景提供了積極的支持。
以下爲今日4位分析師對$Twist Bioscience (TWST.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
